Novome Biotechnologies

company

About

Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$225K
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 2016
Number Of Employee
11 - 50
Operating Status
Active

Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$1.52M
Novome Biotechnologies has raised a total of $1.52M in funding over 2 rounds. Their latest funding was raised on Aug 16, 2018 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 16, 2018 Grant $1.30M 1 National Science Foundation Detail
Dec 8, 2016 Grant $225K 1 National Science Foundation Detail

Investors

Number of Lead Investors
Number of Investors
2
1
Novome Biotechnologies is funded by 1 investors. National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
National Science Foundation Yes Grant